From FDA labels and ClinicalTrials.gov

Do GLP-1s help heart failure?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists heart failure as an approved use, so prescribing one for it would be off-label. SUMMIT (Tirzepatide): In heart failure with preserved ejection fraction and obesity, heart death or worsening heart failure happened in 9.9% on tirzepatide against 15.3% on placebo (hazard ratio 0.62). The difference came from worsening heart failure, 8.0% against 14.2%. Heart deaths were 8 people against 5, which the trial could not separate from chance (hazard ratio 1.58, confidence interval 0.52 to 4.83). N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/39555826). ClinicalTrials.gov lists 36 trials of these medicines on it: 5 with posted results and 6 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 14, 2026.

Published results

What the largest trials on heart failure found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

SUMMIT

Tirzepatide · 731 people · Better than the comparison · Placebo-controlled randomized trial

In heart failure with preserved ejection fraction and obesity, heart death or worsening heart failure happened in 9.9% on tirzepatide against 15.3% on placebo (hazard ratio 0.62). The difference came from worsening heart failure, 8.0% against 14.2%. Heart deaths were 8 people against 5, which the trial could not separate from chance (hazard ratio 1.58, confidence interval 0.52 to 4.83).

N Engl J Med, 2025 (pubmed.ncbi.nlm.nih.gov/39555826)

STEP-HFpEF

Semaglutide · 529 people · Better than the comparison · Placebo-controlled randomized trial

At 52 weeks, a symptom score (KCCQ, 0 to 100) rose 16.6 points on semaglutide 2.4 mg against 8.7 on placebo, and the 6-minute walk grew 21.5 m against 1.2 m.

N Engl J Med, 2023 (pubmed.ncbi.nlm.nih.gov/37622681)

The registry

Trials on heart failure, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide1624
Liraglutide810
Tirzepatide711
Exenatide310
MariTide101
Mazdutide100
Posted results

What trials on heart failure reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
NCT04847557A Study of Tirzepatide (LY3298176) in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) and Obesity: The SUMMIT TrialTirzepatidePhase 3731Change From Baseline in the Kansas City Cardiomyopathy Questionnaire (KCCQ) Clinical Summary Score (CSS) (Score on a scale), Baseline, Week 52. Tirzepatide - MTD: 19.51; Placebo: 12.68.
STEP HFpEF DMResearch Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 DiabetesSemaglutidePhase 3617Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score (Score on a scale), Baseline (week 0), end of treatment (week 52). Semaglutide 2.4 mg: 14.4; Placebo: 7.6.
STEP-HFpEFResearch Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and ObesitySemaglutidePhase 3529Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) (Score on a scale), From baseline (week 0) to end of treatment (week 52). Semaglutide 2.4 mg: 16.8; Placebo: 10.3.
NCT00799435Evaluating the Use of Exenatide in People With Type 2 Diabetes and Diastolic Heart FailureExenatidePhase 42Change in Aortic Stiffness, as Measured by the Change in the Mean Aortic Pulse Wave Velocity (m/sec), Measured at Week 12, Baseline Pulse Wave Velocity. Usual Care: 11.4; Exenatide: 9.3.
FIGHTFunctional Impact of GLP-1 for Heart Failure Treatment (FIGHT)LiraglutidePhase 2300Global Ranking of Predefined Events (rank), Randomization to 180 days. Liraglutide: 145.5; Placebo: 155.7.
Recruiting now

Trials on heart failure taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity (clinicaltrials.gov/study/NCT07037459)MariTidePhase 3Sep 29, 2030
Multifactorial Intervention to Reduce Cardiovascular Disease in Type 1 Diabetes (clinicaltrials.gov/study/NCT06082063)SemaglutidePhase 3Jul 1, 2029
Tailored Exercise Training Study Among Adults With HFpEF (clinicaltrials.gov/study/NCT07223242)SemaglutidePhase 2/3Dec 30, 2026
Effect of Weight Loss on Physical and Cardiac Performance in People With Obesity and Heart Failure (clinicaltrials.gov/study/NCT06423599)SemaglutidePhase 2/3Dec 30, 2027
Epicardial Adipose Tissue Composition and Heart Failure With Preserved Ejection Fraction (clinicaltrials.gov/study/NCT07178145)SemaglutidePhase 4Dec 2029
Incretin Therapies in Obesity-related HFpEF (clinicaltrials.gov/study/NCT07554638)TirzepatidePhase 4Apr 2030
From PubMed

Newest papers on GLP-1s and heart failure

  • Clinical outcomes of GLP-1 receptor agonists VS placebo among patients with heart failure with preserved ejection fraction: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/43033336)

    Meta-analysis · Egypt Heart J · Nov 14, 2026 · Davis E et al.

  • Hemodynamic effects of semaglutide in individuals with heart failure with preserved ejection fraction and obesity: a placebo-controlled randomized clinical trial (pubmed.ncbi.nlm.nih.gov/43000472)

    Randomized trial · Nat Med · Nov 8, 2026 · Borlaug BA et al.

  • GLP-1-based therapies for reduction of heart failure and cardiovascular outcomes: A systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/43024260)

    Meta-analysis · Medicine (Baltimore) · Nov 1, 2026 · Sajid EU et al.

  • Effects of tirzepatide (GIP/GLP-1 dual receptor agonist) on cardiorenal biomarkers and functional capacity in heart failure: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42867450)

    Meta-analysis · J Clin Endocrinol Metab · Oct 13, 2026 · Eisa N et al.

  • GLP-1 Receptor Agonists in Heart Failure: A Systematic Review and Meta-analysis with Phenotype-Specific Effects and Dual Analytical Frameworks (pubmed.ncbi.nlm.nih.gov/42791433)

    Meta-analysis · Drugs · Sep 26, 2026 · Yuan Y et al.

  • The effects of tirzepatide and semaglutide on clinical and metabolic outcomes in patients with heart failure with preserved ejection fraction and obesity: a systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42772984)

    Meta-analysis · Nutr Metab Cardiovasc Dis · Sep 8, 2026 · AlAraibi AJ et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on heart failure

  • TrialResults posted for a Semaglutide study: Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes (clinicaltrials.gov/study/NCT04916470)
  • TrialLiraglutide study now completed (was unknown): Incretin and Treatment With Inhibition of Sodium-glucose Cotransporter-2 Combination Insights Into Mechanisms Implicated in Congestive Heart Failure: "NATRIURETIC" Trial (clinicaltrials.gov/study/NCT04535960)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and heart failure: common questions

What did the largest trial on heart failure find?

SUMMIT (Tirzepatide, 731 people): In heart failure with preserved ejection fraction and obesity, heart death or worsening heart failure happened in 9.9% on tirzepatide against 15.3% on placebo (hazard ratio 0.62). The difference came from worsening heart failure, 8.0% against 14.2%. Heart deaths were 8 people against 5, which the trial could not separate from chance (hazard ratio 1.58, confidence interval 0.52 to 4.83).

Is any GLP-1 FDA approved for heart failure?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for heart failure?

Semaglutide, with 16 registered trials on it, then Liraglutide with 8. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for heart failure?

6 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.